Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410547 | 0.84 | ALDH1A1 (0.54) | ALDH1A1CA12CA9ELANEKMT2A | |
| SCHEMBL13459842 | 0.84 | CA12 (0.55) | ALDH1A1CA12CA9ELANEKMT2A | |
| SCHEMBL9429799 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CA12CA9ELANEKMT2A | |
| SCHEMBL9429796 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CA12CA9ELANEKMT2A | |
| SCHEMBL4405142 | 0.80 | ALDH1A1 (0.54) | ALDH1A1CA12CA9ELANEKMT2A | |
| SCHEMBL17280822 | 0.78 | ALDH1A1 (0.64) | ALDH1A1CA12CA9ELANEKMT2A | |
| SCHEMBL6699242 | 0.78 | ALDH1A1 (0.64) | ALDH1A1CA12CA9ELANEKMT2A | |
| SCHEMBL3435525 | 0.78 | ALDH1A1 (0.64) | ALDH1A1CA12CA9ELANEKMT2A | |
| SCHEMBL29163025 | 0.78 | ALDH1A1 (0.47) | ALDH1A1CA12CA9ELANEKMT2A | |
| SCHEMBL9340887 | 0.77 | ALDH1A1 (0.53) | ALDH1A1CA12CA9ELANEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8728688-B2 | Colored curable composition, color filter and method of producing the same, and dipyrromethene metal complex compound and tautomer thereof | FUJIFILM CORPORATION (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20120315579-A1 | COLORED CURABLE COMPOSITION, COLOR FILTER AND METHOD OF PRODUCING THE SAME, AND DIPYRROMETHENE METAL COMPLEX COMPOUND AND TAUTOMER THEREOF | FUJIFILM CORPORATION (JP) | 2012-12-13 | — | — | US | disclosed |
| EP-0333938-B1 | 2-HYDROXY-3-ARYLOXY-PROPYLAMINE DERIVATIVES HAVING CARDIOVASCULAR ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 1993-04-14 | — | — | EP | disclosed |
| EP-0198325-B1 | SUBSTITUTED ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1992-07-15 | — | — | EP | disclosed |
| US-4891429-A | CHEMICAL INTERMEDIATES | HOFFMANN-LA ROCHE INC. (US) | 1990-01-02 | — | — | US | disclosed |
| EP-0333938-A1 | 2-Hydroxy-3-aryloxy-propylamine derivatives having cardiovascular activity | ZAMBON GROUP S.p.A. (IT) | 1989-09-27 | — | — | EP | disclosed |
| US-4696930-A | CARDIOVASCULAR DISORDERS, ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1987-09-29 | — | — | US | disclosed |
| EP-0198325-A2 | Substituted aniline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1986-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315579-A1 | COLORED CURABLE COMPOSITION, COLOR FILTER AND METHOD OF PRODUCING THE SAME, AND DIPYRROMETHENE METAL COMPLEX COMPOUND AND TAUTOMER THEREOF | MAPT, UACA, HELZ | ALDH1A1 3722/4885CA12 183/4885CA9 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.